NASDAQ:IFRX

InflaRx Q1 2025 Earnings Results & Report

InflaRx logo
$1.15 -0.03 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 -0.03 (-2.52%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 7, 2025. The company reported EPS of -$0.14 versus the -$0.18 consensus estimate, while revenue of $27 thousand fell short of the $34 thousand estimate by $7.00 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

InflaRx EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

InflaRx Revenue Results

Actual Revenue
$27 thousand
Expected Revenue
$34 thousand
Beat/Miss
Missed by -$7.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

InflaRx Q1 2025 Earnings FAQ

InflaRx (NASDAQ:IFRX) reported earnings of -$0.14 per share for Q1 2025, beating the consensus estimate of -$0.18. The report was announced on Wednesday, May 7, 2025.

InflaRx reported revenue of $27 thousand for Q1 2025, against a consensus estimate of $34 thousand.

InflaRx Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
InflaRx (IFRX) AI Stock Analysis
InflaRx Stock Gets Stronger EPS Forecast from HC Wainwright
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage.

The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.

View InflaRx Profile